Market Cap 62.28M
Revenue (ttm) 30,000.00
Net Income (ttm) -14.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -47,633.33%
Debt to Equity Ratio 0.00
Volume 425,200
Avg Vol 365,852
Day's Range N/A - N/A
Shares Out 51.90M
Stochastic %K 26%
Beta 0.69
Analysts Strong Sell
Price Target $3.17

Company Profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acu...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 650 216 3500
Address:
1850 Gateway Drive, Suite 175, San Mateo, United States
firedupinvestors
firedupinvestors Aug. 18 at 10:38 PM
$TLPH are we heading back under $1?
0 · Reply
Estimize
Estimize Aug. 18 at 8:00 PM
Wall St is expecting -0.05 EPS for $TLPH Q3 [Reporting 11/16 AMC] http://www.estimize.com/intro/tlph?chart=historical&metric_name=eps&utm_c
0 · Reply
Yoda896
Yoda896 Aug. 17 at 4:24 PM
$TLPH ...Continued from previous message C) Restrictions that may be included in the FDA approval: * Initially, approval may restrict patients under 110 lb, younger than 18 or older than 80. * May include warnings or contraindications for drug allergy, uncontrolled catastrophic bleeding such as major intracranial hemorrhage, severe coagulopathy, or concomitant systemic anticoagulation.
0 · Reply
Yoda896
Yoda896 Aug. 17 at 4:21 PM
$TLPH ...Continued from previous message B) The FDA approval will be a lot less restrictive: * The clinical trial is restrictive because it must clearly distinguish adverse events and efficacy caused by Niyad from those caused by other factors. Upon successful phase III results, most restrictions become irrelevant for FDA approval. * The benefits of Niyad are weighed against not using it. * There are no enrollment deadlines. * There is no consent process. * The patient does not need to enter CRRT at a particular time. * Patients with ACT above 150 can still benefit from Niyad. * Patients with liver disease or moderate coagulation abnormalities need Niyad because they have problems with Citrate and Heparin. Continued in next message...
0 · Reply
Yoda896
Yoda896 Aug. 17 at 4:17 PM
$TLPH A) Enrollment is slow because it's very restrictive: * Most arrive bleeding and could not be enrolled until bleeding had stabilized, assuming the patient is still on CRRT. * Most patients cannot be enrolled because their Baseline ACT (Activated Clotting Time) is over 150 seconds. * Cannot enroll liver patients, patients with coagulopathy, patients under 110 lb, patients younger than 18 or older than 80. * Cannot enroll patients without their consent or a surrogate consent. Patient consent is hard to get because most are critically ill, unconscious, intubated or unstable. Surrogate consent is hard to get because you need a bunch of things to happen at the same time, including research personnel, nephrology and ICU agreement, acceptable laboratory results and the patient. Continued in next message...
1 · Reply
Crandaddy01
Crandaddy01 Aug. 17 at 3:52 PM
0 · Reply
RunningRobert1
RunningRobert1 Aug. 17 at 1:24 PM
$TLPH Talphera TLPH Q2 2026 Summary 14Aug2026 https://youtu.be/WATxL7A8bYY Were all just playing the waiting game, the market def didn't like that enrollment hasn't moved that fast, but I believe more then enough of us know or have posted, that they will have data long before money becomes an issues, sadly we just have to wait
1 · Reply
Yoda896
Yoda896 Aug. 15 at 4:06 PM
$TLPH * On March 2nd, 50% were enrolled. * On August 12th, 75% were enrolled. * Thus, it took 163 days to enroll 25%. * Assume they need another 163 days to enroll the last 25%. * 163 days after August 12th would be January 22nd. * That would make January 22nd the day of completion of enrollment. * However, enrollment in the next few months should be a bit faster. It would be faster because all 14 centers are now enrolling and managed by top nephrologists. Also, enrollments are always faster as you approach the end. When most have been enrolled without adverse events, doctors and patients become less hesitant to enroll. * If enrollment rate is only 15% faster, enrollment would be done in 163x85%=138.55 days. Let's say 139 days. * 139 days after August 12th would be December 29. * Conclusion: January 22nd at the latest, but December 29 more likely. * What's more comforting than the potential dates of completion is the fact that those dates are now 100% guaranteed. No more WILD guesses required.
0 · Reply
AlwaysRational
AlwaysRational Aug. 13 at 6:58 PM
$TLPH Vince Angotti: King of the Delays.
0 · Reply
biotrade123
biotrade123 Aug. 13 at 4:33 PM
$TLPH Nice P&D on the run up to the ER😰😪
0 · Reply
Latest News on TLPH
Talphera Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Talphera Earnings Call Transcript: Q2 2026


Talphera Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Talphera Earnings release: Q2 2026


Talphera Quarterly report: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Talphera Quarterly report: Q2 2026


Talphera Transcript: AGM 2026

Jun 22, 2026, 1:00 PM EDT - 2 months ago

Talphera Transcript: AGM 2026


Talphera assumed with a Buy at H.C. Wainwright

2026-06-05T10:27:07.000Z - 2 months ago

Talphera assumed with a Buy at H.C. Wainwright


Talphera reports Q1 EPS (4c) vs. (10c) last year

2026-05-13T21:03:38.000Z - 3 months ago

Talphera reports Q1 EPS (4c) vs. (10c) last year


Talphera Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Talphera Earnings Call Transcript: Q1 2026


Talphera Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Talphera Earnings release: Q1 2026


Talphera Quarterly report: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Talphera Quarterly report: Q1 2026


Talphera initiated with a Buy at WestPark Capital

2026-04-30T18:25:47.000Z - 3 months ago

Talphera initiated with a Buy at WestPark Capital


Talphera Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Talphera Proxy statement: Proxy filing


Talphera Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Talphera Proxy statement: Proxy filing


Talphera Slides: Corporate presentation

Apr 9, 2026, 7:00 AM EDT - 4 months ago

Talphera Slides: Corporate presentation


Talphera Registration statement: Registration filing

Mar 25, 2026, 8:00 AM EDT - 5 months ago

Talphera Registration statement: Registration filing


Talphera Earnings Call Transcript: Q4 2025

Mar 23, 2026, 11:00 AM EDT - 5 months ago

Talphera Earnings Call Transcript: Q4 2025


Talphera Annual report: Q4 2025

Mar 23, 2026, 11:00 AM EDT - 5 months ago

Talphera Annual report: Q4 2025


Talphera Earnings release: Q4 2025

Mar 23, 2026, 11:00 AM EDT - 5 months ago

Talphera Earnings release: Q4 2025


Talphera reports Q4 EPS (6c) vs. (7c) last year

2026-03-23T12:41:43.000Z - 5 months ago

Talphera reports Q4 EPS (6c) vs. (7c) last year


Talphera Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Talphera Earnings Call Transcript: Q3 2025


Talphera Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Talphera Quarterly report: Q3 2025


Talphera Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Talphera Earnings release: Q3 2025


Talphera reports Q3 EPS (11c) vs. (13c) last year

2025-11-12T21:23:13.000Z - 9 months ago

Talphera reports Q3 EPS (11c) vs. (13c) last year


Talphera files to sell 1.02M shares of common stock for holders

2025-10-28T20:36:26.000Z - 10 months ago

Talphera files to sell 1.02M shares of common stock for holders


Talphera Registration statement: Registration Filing

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Talphera Registration statement: Registration Filing


Talphera files to sell 25.04M shares of common stock for holders

2025-09-22T21:15:15.000Z - 11 months ago

Talphera files to sell 25.04M shares of common stock for holders


Talphera Registration statement: Registration Filing

Sep 22, 2025, 8:00 AM EDT - 11 months ago

Talphera Registration statement: Registration Filing


Talphera Proxy statement: Proxy Filing

Sep 9, 2025, 8:00 AM EDT - 1 year ago

Talphera Proxy statement: Proxy Filing


Talphera Proxy statement: Proxy Filing

Sep 9, 2025, 8:00 AM EDT - 1 year ago

Talphera Proxy statement: Proxy Filing


CorMedix makes $5M minority equity investment in Talphera

2025-09-08T12:45:47.000Z - 1 year ago

CorMedix makes $5M minority equity investment in Talphera

CRMD


Talphera Proxy statement: Proxy Filing

Aug 29, 2025, 8:00 AM EDT - 1 year ago

Talphera Proxy statement: Proxy Filing


Talphera Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Talphera Earnings Call Transcript: Q2 2025


Talphera Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Talphera Quarterly report: Q2 2025


Talphera Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Talphera Earnings release: Q2 2025


Talphera reports Q2 EPS (10c) vs. (15c) last year

2025-08-14T20:16:22.000Z - 1 year ago

Talphera reports Q2 EPS (10c) vs. (15c) last year


Talphera Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Talphera Earnings Call Transcript: Q1 2025


Talphera Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Talphera Quarterly report: Q1 2025


Talphera Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Talphera Earnings release: Q1 2025


Talphera reports Q1 EPS (10c), consensus (14c)

2025-05-14T20:17:58.000Z - 1 year ago

Talphera reports Q1 EPS (10c), consensus (14c)


Talphera sees 2025 expenses $17M-$19M

2025-05-14T20:17:33.000Z - 1 year ago

Talphera sees 2025 expenses $17M-$19M


Talphera Registration statement: Registration Filing

May 2, 2025, 8:00 AM EDT - 1 year ago

Talphera Registration statement: Registration Filing


Talphera Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Talphera Earnings Call Transcript: Q4 2024


Talphera Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Talphera Annual report: Q4 2024


Talphera Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Talphera Earnings release: Q4 2024


Talphera reports Q4 EPS (7c) vs. (25c) last year

2025-03-31T20:11:33.000Z - 1 year ago

Talphera reports Q4 EPS (7c) vs. (25c) last year


Talphera Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Talphera Earnings Call Transcript: Q3 2024


Talphera Quarterly report: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Talphera Quarterly report: Q3 2024


Talphera Earnings release: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Talphera Earnings release: Q3 2024


Talphera Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Talphera Earnings Call Transcript: Q2 2024


Talphera Quarterly report: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Talphera Quarterly report: Q2 2024


Talphera Earnings release: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Talphera Earnings release: Q2 2024


Talphera to Participate at A.G.P. Virtual Healthcare Conference

May 16, 2024, 5:45 PM EDT - 2 years ago

Talphera to Participate at A.G.P. Virtual Healthcare Conference


Talphera Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Talphera Earnings Call Transcript: Q1 2024


Talphera Quarterly report: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Talphera Quarterly report: Q1 2024


Talphera Earnings release: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Talphera Earnings release: Q1 2024


Talphera Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Talphera Proxy statement: Proxy Filing


Talphera Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Talphera Proxy statement: Proxy Filing


Talphera Earnings Call Transcript: Q4 2023

Mar 6, 2024, 4:30 PM EST - 2 years ago

Talphera Earnings Call Transcript: Q4 2023


Talphera Annual report: Q4 2023

Mar 6, 2024, 4:30 PM EST - 2 years ago

Talphera Annual report: Q4 2023


Talphera Earnings release: Q4 2023

Mar 6, 2024, 4:30 PM EST - 2 years ago

Talphera Earnings release: Q4 2023


Talphera Registration statement: Registration Filing

Feb 6, 2024, 7:00 AM EST - 2 years ago

Talphera Registration statement: Registration Filing


firedupinvestors
firedupinvestors Aug. 18 at 10:38 PM
$TLPH are we heading back under $1?
0 · Reply
Estimize
Estimize Aug. 18 at 8:00 PM
Wall St is expecting -0.05 EPS for $TLPH Q3 [Reporting 11/16 AMC] http://www.estimize.com/intro/tlph?chart=historical&metric_name=eps&utm_c
0 · Reply
Yoda896
Yoda896 Aug. 17 at 4:24 PM
$TLPH ...Continued from previous message C) Restrictions that may be included in the FDA approval: * Initially, approval may restrict patients under 110 lb, younger than 18 or older than 80. * May include warnings or contraindications for drug allergy, uncontrolled catastrophic bleeding such as major intracranial hemorrhage, severe coagulopathy, or concomitant systemic anticoagulation.
0 · Reply
Yoda896
Yoda896 Aug. 17 at 4:21 PM
$TLPH ...Continued from previous message B) The FDA approval will be a lot less restrictive: * The clinical trial is restrictive because it must clearly distinguish adverse events and efficacy caused by Niyad from those caused by other factors. Upon successful phase III results, most restrictions become irrelevant for FDA approval. * The benefits of Niyad are weighed against not using it. * There are no enrollment deadlines. * There is no consent process. * The patient does not need to enter CRRT at a particular time. * Patients with ACT above 150 can still benefit from Niyad. * Patients with liver disease or moderate coagulation abnormalities need Niyad because they have problems with Citrate and Heparin. Continued in next message...
0 · Reply
Yoda896
Yoda896 Aug. 17 at 4:17 PM
$TLPH A) Enrollment is slow because it's very restrictive: * Most arrive bleeding and could not be enrolled until bleeding had stabilized, assuming the patient is still on CRRT. * Most patients cannot be enrolled because their Baseline ACT (Activated Clotting Time) is over 150 seconds. * Cannot enroll liver patients, patients with coagulopathy, patients under 110 lb, patients younger than 18 or older than 80. * Cannot enroll patients without their consent or a surrogate consent. Patient consent is hard to get because most are critically ill, unconscious, intubated or unstable. Surrogate consent is hard to get because you need a bunch of things to happen at the same time, including research personnel, nephrology and ICU agreement, acceptable laboratory results and the patient. Continued in next message...
1 · Reply
Crandaddy01
Crandaddy01 Aug. 17 at 3:52 PM
0 · Reply
RunningRobert1
RunningRobert1 Aug. 17 at 1:24 PM
$TLPH Talphera TLPH Q2 2026 Summary 14Aug2026 https://youtu.be/WATxL7A8bYY Were all just playing the waiting game, the market def didn't like that enrollment hasn't moved that fast, but I believe more then enough of us know or have posted, that they will have data long before money becomes an issues, sadly we just have to wait
1 · Reply
Yoda896
Yoda896 Aug. 15 at 4:06 PM
$TLPH * On March 2nd, 50% were enrolled. * On August 12th, 75% were enrolled. * Thus, it took 163 days to enroll 25%. * Assume they need another 163 days to enroll the last 25%. * 163 days after August 12th would be January 22nd. * That would make January 22nd the day of completion of enrollment. * However, enrollment in the next few months should be a bit faster. It would be faster because all 14 centers are now enrolling and managed by top nephrologists. Also, enrollments are always faster as you approach the end. When most have been enrolled without adverse events, doctors and patients become less hesitant to enroll. * If enrollment rate is only 15% faster, enrollment would be done in 163x85%=138.55 days. Let's say 139 days. * 139 days after August 12th would be December 29. * Conclusion: January 22nd at the latest, but December 29 more likely. * What's more comforting than the potential dates of completion is the fact that those dates are now 100% guaranteed. No more WILD guesses required.
0 · Reply
AlwaysRational
AlwaysRational Aug. 13 at 6:58 PM
$TLPH Vince Angotti: King of the Delays.
0 · Reply
biotrade123
biotrade123 Aug. 13 at 4:33 PM
$TLPH Nice P&D on the run up to the ER😰😪
0 · Reply
Brunoez
Brunoez Aug. 13 at 4:13 PM
$TLPH I don't think we'll go all the way back to .70, but I believe $1.00 may be in play in the next few months. I sold all but 10K shares AH last night. My original plan was to ride it out to the finish line, but this additional 3 month delay is going to hurt the share price. Might as well play the dip.
1 · Reply
nazzangr
nazzangr Aug. 13 at 1:45 PM
$TLPH this drop is very uncalled for. I wouldve picked more shares up if i had more cash!
0 · Reply
CaliEmpress
CaliEmpress Aug. 12 at 11:05 PM
$TLPH I was honestly expecting a higher completion rate but I now understand how complicated the enrollment is. I was happy to hear that the safety data was immaculate and the users “can’t wait to start using it”. My projected goal is now extended by 2 months. That’s more Long term vs. short term gain for me.
2 · Reply
Noname2022
Noname2022 Aug. 12 at 10:50 PM
$CRMD $TLPH https://m.investing.com/news/transcripts/earnings-call-transcript-talphera-q2-2026-meets-estimates-as-stock-slips-93CH-4856227?ampMode=1
3 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 12 at 10:09 PM
$TLPH Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.06 up 40.00% YoY
0 · Reply
EarningsInsider
EarningsInsider Aug. 12 at 9:15 PM
https://www.marketbeat.com/earnings/reports/2026-8-12-talphera-inc-stock/ $TLPH Talphera Earnings Transcript
0 · Reply
Acemaker12
Acemaker12 Aug. 12 at 9:07 PM
$TLPH overall I thought it was a pretty good call. Their expert is very good.
1 · Reply
Brunoez
Brunoez Aug. 12 at 8:40 PM
$TLPH 50% enrollment was announced on Mar2 = 35 patients. That means that they only signed up an additional 18 patients since then over a period of 23 weeks. That is well under 1 patient per week.
2 · Reply
Noname2022
Noname2022 Aug. 12 at 8:36 PM
$CRMD $TLPH Niyad 75% enrolled!
1 · Reply
Briguy25
Briguy25 Aug. 12 at 8:31 PM
$TLPH ive been bullish on this for the past 7-8 months. -.06 per share instead of expected -.07!!! 75% enrolled. I did a write up a few months ago on reddit
0 · Reply
TwongStocks
TwongStocks Aug. 12 at 8:14 PM
$CRMD TLPH disclosed that they hit 75% enrollment in the NEPHRO-CRRT trial and are tracking for completion by end of this year. https://www.sec.gov/ix?doc=/Archives/edgar/data/1427925/000143774926027311/acrx20260811_8k.htm CRMD will have an exclusive option to negotiate an acquisition of $TLPH if primary endpoint is met in that trial.
2 · Reply
mrty
mrty Aug. 12 at 8:10 PM
$TLPH https://ir.talphera.com/node/15461/pdf
0 · Reply